P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort

Yoon‐Kyo An(Mater Hospital), Jakob Begun(Translational Research Institute), Lauren S. White(Sunshine Coast University Hospital), Astrid‐Jane Williams, Daniel Lightowler(The University of Western Australia), Peter De Cruz(The University of Melbourne), Anna Amiss(Mater Research), Rupert W. Leong(The University of Sydney), G. Radford‐Smith(European CanCer Organisation), Britt Christensen(The Royal Melbourne Hospital), R V Bryant(Queen Elizabeth Hospital), Kavitha Subramaniam(Australian National University), Daniel R. van Langenberg(Eastern Health), Jane M. Andrews(Health Net), Simon Ghaly(UNSW Sydney), Lena Thin(The University of Western Australia), Soong‐Yuan Ooi(Royal Brisbane and Women's Hospital), C Li Wai Suen(The University of Melbourne), K F Wong(Mater Research), Susan J. Connor(Liverpool Hospital), Viraj C. Kariyawasam(Concord Repatriation General Hospital), Nikola Mitrev(Blacktown & Mount Druitt Hospital), Nik S. Ding(The University of Melbourne), Richard Fernandes(The University of Queensland), Emi Khoo(The University of Queensland), Huong T. T. Pham(Mater Research), Miles Sparrow(Alfred Health), Hansjoerg Seltenreich(University of the Sunshine Coast), Natalie Allan(Mater Research), Niamh Lindsay(Mater Research)
Journal of Crohn s and Colitis
January 30, 2023
Cited by 0


Related Papers